Johannes Czernin, MD
Nuclear Medicine · Los Angeles, CANPI 1942245758
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), consulting fees and grants — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Pfizer at 54.2% of the total. Reporting peaked in 2022 at $10,223 and has fallen 71.0% since, to $2,967 in 2023. Among nuclear medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $1411.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$13K
- Advanced Accelerator Applications$8K
- Amgen$2K
- Sanofi$430
- Voximetry, Inc.$167
- Boston Scientific$31
- plus $47 from 2 others
Across 5 payments — averaging $57,128 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$253K
- Ipsen Pharma SAS$32K
What the payments were for
- Consulting fees$6,66228%
- Speaking & faculty fees$13,00054%
- Grants$3,00012%
- Travel & lodging$7483%
- Food & beverage$5922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $13,000 |
| Advanced Accelerator Applications | 4 | $8,443 |
| Amgen | 1 | $1,884 |
| Sanofi | 2 | $430 |
| Voximetry, Inc. | 1 | $167 |
| Boston Scientific | 1 | $31 |
| GE HealthCare | 1 | $24 |
| Novartis | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$13,000
- Lutathera$3,000
- NO PRODUCT DISCUSSED$430
- Torch$167
How this compares
$24,002 in reported general payments places this provider in the 95th percentile of 110 nuclear medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nuclear medicine in Los Angeles
- Hossein JadvarLos Angeles$294K
- Gholam BerenjiLos Angeles$15K
- Shahram BonyadlouLos Angeles$12K
- Daniel SilvermanLos Angeles$8K
- Patrick CollettiLos Angeles$578
- Do KimLos Angeles$508
- David WinsorLos Angeles$136
- Shadfar BahriLos Angeles$80
- Louise ThomsonLos Angeles$31
- Michael DaeSan Francisco$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.